Rachel K. King
CIK 1589712 · President, CEO · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$356.4K
Companies
3
Total Filings
37
Lifetime Open-Market Net
-$223.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 3 of 4
37 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-22 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | NVAX | Buy (P) | +700 | $97.7K | EDGAR |
| 2021-01-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +96,250 | $0 | EDGAR |
| 2020-12-30 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Mixed | +46,645 | -$182.6K | EDGAR |
| 2020-06-26 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2020-01-24 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-12-16 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2019-08-07 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Exer (M) | +166,759 | $186.8K | EDGAR |
| 2019-03-28 | NVAX | Buy (P) | +86,000 | $45.6K | EDGAR |
| 2019-01-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.